-

Toragen, Inc. Announces Appointment of Chief Scientific Officer

Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)

SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.

Dr. Lumpkin joined Toragen in late 2018 as a consultant and became a fulltime employee in mid-2022. Sandra Coufal, MD, Toragen’s CEO said, “We are thrilled to have Rick as our Chief Scientific Officer as he brings over 30 years of significant experience in early-stage biotechnology companies and synthetic chemistry. Rick has already made important discoveries at Toragen and has directed the foundational science to swiftly proceed to the clinic.”

Prior to Toragen, Dr. Lumpkin served as a founding employee at Global Blood Therapeutics, Portola Pharmaceuticals and Millennium Pharmaceuticals. Additionally, Dr. Lumpkin brings experience from COR Therapeutics, Ribogene, Amylin and Corvas International, Inc.

About Toragen

Toragen, Inc. is targeting the root cause of virally induced cancers. https://toragen.com.

Contacts

Toragen, Inc.
Cheryl Collett
CFO
ccollett@toragen.com

Toragen, Inc.


Release Versions

Contacts

Toragen, Inc.
Cheryl Collett
CFO
ccollett@toragen.com

More News From Toragen, Inc.

Toragen, Inc. Provides Update on Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® in Patients with Stage 4 HPV-Associated Cancers

SAN DIEGO--(BUSINESS WIRE)--Today, Toragen, Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from its Phase 1 trial of TGN-S11, a small molecule inhibitor of the human papillomavirus (HPV) E5 oncogene protein, in patients with cancers associated with HPV. This Phase 1 trial was an open-label, non-randomized study in multiple cohorts of patients with relapsed, resistant,...

Toragen, Inc. Provides Update on Data from Ongoing Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® (pembrolizumab) in Patients with Stage 4 Human Papillomavirus-Associated Cancers

SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc. provides update on data from its ongoing Phase 1 Clinical Trial of TGN-S11 in patients with Stage 4 HPV-associated cancers....

Toragen, Inc. Announced Positive Safety Data Update from Cohort 2 and the Initiation of its Dose Expansion of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer

SAN DIEGO--(BUSINESS WIRE)--Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 2 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers. This Phase 1 trial is an open-label, non-randomized study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The study is being co...
Back to Newsroom